基于肠道嗜性血清型41的新型腺病毒疫苗载体。

Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

作者信息

Lemiale Franck, Haddada Hedi, Nabel Gary J, Brough Douglas E, King C Richter, Gall Jason G D

机构信息

Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, United States.

出版信息

Vaccine. 2007 Mar 1;25(11):2074-84. doi: 10.1016/j.vaccine.2006.11.025. Epub 2006 Nov 28.

Abstract

Replication-defective adenovirus vectors, primarily developed from serotype 5 (Ad5) viruses, have been widely used for gene transfer and vaccination approaches. Vectors based on other serotypes of adenovirus could be used in conjunction with, or in place of, Ad5 vectors. In this study, Ad41, an enteric adenovirus usually described as 'non-cultivable' or 'fastidious,' has been successfully cloned, rescued and propagated on 293-ORF6 cells. The complementation capabilities of this cell line allow generation of Ad41 vectors at titers comparable to those obtained for Ad5 vectors. Mice immunized with an Ad41 vector containing an HIV envelope (Env) gene mounted anti-Env cellular and humoral immune responses. Ad41-Env vectors appear to be particularly attractive when used in heterologous prime-boost regimens, where they induce significantly higher cellular immune responses to HIV-Env than Ad5-based regimens. Ad41-based constructs are attractive vaccine vectors alone or in combination with Ad5 adenovectors, since each vector type can provide circumvention of pre-existing immunity to the other.

摘要

复制缺陷型腺病毒载体主要由5型(Ad5)病毒开发而来,已广泛用于基因转移和疫苗接种方法。基于其他腺病毒血清型的载体可与Ad5载体联合使用或替代Ad5载体。在本研究中,Ad41,一种通常被描述为“不可培养”或“苛求”的肠道腺病毒,已成功克隆,并在293-ORF6细胞上拯救和繁殖。该细胞系的互补能力使得能够产生滴度与Ad5载体相当的Ad41载体。用含有HIV包膜(Env)基因的Ad41载体免疫的小鼠产生了抗Env细胞免疫和体液免疫反应。当用于异源初免-加强方案时,Ad41-Env载体似乎特别有吸引力,在该方案中,它们诱导的针对HIV-Env的细胞免疫反应明显高于基于Ad5的方案。基于Ad41的构建体单独或与Ad5腺病毒载体联合使用都是有吸引力的疫苗载体,因为每种载体类型都可以规避对另一种载体的预先存在的免疫。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索